La importancia de los biomarcadores de insuficiencia cardiaca postinfarto de miocardio: una revisión sistemática.

• Autores: Vásquez-Donet, C.A., Bazualdo-Fiorini, E.R., Saavedra-Alvarado, T.W., Portilla-Linares, M.M., Valdez-Portilla, J., Barrera-Benavides, L.G.
• Formato: revisión
• Fecha de Publicación: 2023
• Institución: Universidad Nacional de Cajamarca
• Repositorio: UNC-Institucional
• Lenguaje: español
• OAI Identifier: oai:repositorio.unc.edu.pe:20.500.14074/10204
• Enlace del recurso: http://hdl.handle.net/20.500.14074/10204; https://doi.org/10.56294/hl2023262
• Nivel de acceso: acceso abierto
• Materia: Heart failure; cardiac remodeling; biomarkers; post myocardial infarction; https://purl.org/pe-repo/ocde/ford#3.02.04

Heart failure (HF) after a myocardial infarction (MI) is one of the most frequent complications and with the highest mortality rate in the population. Given this, the importance of finding appropriate biomarkers for the diagnosis, prognosis and treatment of this condition. The review was carried out under an analytical approach, using the PRISMA statement as a methodology; for this, documents were retrieved through the Scopus, ScienceDirect and PubMed databases, where 20 articles that met certain inclusion criteria were recognized. In conclusion, it was explained that the use of standard biomarkers such as B-type natriuretic peptide (BNP) and non-terminal pro-BNP in clinical practice have limitations, especially due to their low specificity for HF as a post-MI complication. Therefore, currently, biomarkers that reflect the alteration of cardiac integrity, biomarkers of cardiac injury and necrosis, inflammatory biomarkers, biomarkers of cardiac fibrosis, biomarkers of biomechanical myocardial stress, and other types of biomarkers such as non-coding RNAs are being investigated.